Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT07179042
EARLY_PHASE1

Intertrochanteric Femur Fracture Patients Who Receive Metformin With a Placebo

Sponsor: University of Utah

View on ClinicalTrials.gov

Summary

The investigators central hypothesis is that metformin supplementation will be well-tolerated, safe, and provide patients with improved functional and muscle morphology outcomes following intertrochanteric femur fracture. The objectives will be tested in older adults that sustain a hip fracture and are randomized to receive a daily oral dose (1.5g daily) of metformin or a non-active placebo during 4 months of recovery following surgery.

Official title: A Pilot Study to Assess the Feasibility of a Randomized, Double-blind, Placebo-controlled Trial Investigating Intertrochanteric Femur Fracture Patients Who Receive Metformin With a Placebo

Key Details

Gender

All

Age Range

60 Years - 90 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2025-09-04

Completion Date

2030-09

Last Updated

2025-09-17

Healthy Volunteers

No

Interventions

DRUG

Placebo

Placebo tablets will be dispensed to the participants for 119-days.

DRUG

Metformin

Metformin tablets will be dispensed to the participants for 119-days.

Locations (1)

University of Utah Orthopedics

Salt Lake City, Utah, United States